Vital Signs

Showing 41-50 of 307

Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...

USD 450.00

USD 337.50 save 25 %

06 Apr 2014  |  North America

Vital Signs - What’s New in Medical Imaging Advanced Visualization?

Evolving Customer Demands Spurring Competitive Dynamics

Ongoing technology and clinical advances in every imaging modality continue to bring advanced visualization (AV) and clinical applications to centerstage. AV is not just a core step in the interpretation workflow of each of these modalities, but essentially the set of solutions that allows to realize the promises of the advances on the equipment si...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.

USD 450.00

USD 337.50 save 25 %

In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on November 22, 2013, provides overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market. Additionally, a company spotlight is provided for Global BioDiagnostics based in Temple, Texas. The company is focused on developing affordable diagnostic tes...

USD 450.00

USD 337.50 save 25 %

The following Vital Signs presents highlights from our attendance at Health 2.0 in Santa Clara, CA. This meeting is held every fall in the San Francisco area and is considered to be one of the premier events to gage the latest trends in disruptive health IT, particularly related to consumer health and patient engagement. We discuss our perspectives...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on October 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, and Advanced Medical Technology.

USD 450.00

USD 337.50 save 25 %

Showing 41-50 of 307